Advertisement

ADVERTISEMENT

cancer care costs

News
Higher Out-of-Pocket Costs Associated With Decreased TKI Adherence in NSCLC
02/15/2021
02/15/2021
Journal of Clinical Pathways
News
Cost-Sharing Patterns for PARP Inhibitor Therapy in Ovarian Cancer
02/12/2021
02/12/2021
Journal of Clinical Pathways
Real-World Treatment Patterns, HCRU in Patients With CML Achieving Later Lines of Therapy
ENGAGING EXPERTS
Real-World Treatment Patterns, HCRU in Patients With CML Achieving Later Lines of Therapy
01/14/2021
Ehab Atallah, MD, discusses results from a study evaluating treatment patterns in patients with CML achieving later lines of therapy, and estimating the associated HCRU and costs.
Ehab Atallah, MD, discusses results from a study evaluating treatment patterns in patients with CML achieving later lines of therapy, and estimating the associated HCRU and costs.
Ehab Atallah, MD, discusses...
01/14/2021
Journal of Clinical Pathways
News
Real-World Costs of First-Line Prostate Cancer Management Strategies
01/05/2021
01/05/2021
Journal of Clinical Pathways
News
Timely Specialty Palliative Care for NSCLC Associated With Cost-Savings
12/17/2020
12/17/2020
Journal of Clinical Pathways
HCRU, Costs With CAR-T Therapy Compared to Transplantation for DLBCL
Videos
HCRU, Costs With CAR-T Therapy Compared to Transplantation for DLBCL
12/17/2020
Karl Kilgore, PhD, discusses study results that showed greater HCRU and costs with CAR-T therapy than transplantation for patients with relapsed/refractory DLBCL.
Karl Kilgore, PhD, discusses study results that showed greater HCRU and costs with CAR-T therapy than transplantation for patients with relapsed/refractory DLBCL.
Karl Kilgore, PhD, discusses...
12/17/2020
Journal of Clinical Pathways
News
Comparison of Costs, Outcomes Among Neoadjuvant-Adjuvant Treatment Strategies for Breast Cancer
12/08/2020
12/08/2020
Journal of Clinical Pathways
Conference Coverage
Polatuzumab Vedotin Plus Bendamustine-Rituximab Cost-Effective for DLBCL
12/05/2020
12/05/2020
Journal of Clinical Pathways
Research Reports
Community Oncologists` Perception and Acceptance of Biosimilars in Oncology
09/13/2018
Chadi Nabhan, MD, MBA, FACP
Yolaine Jeune-Smith, PhD
Amy Valley, PharmD
Bruce A Feinberg, DO
Abstract: Biosimilars are hypothesized to contribute to lowering health care costs by entering the market at a discounted price compared with their reference biologics. Until recently, only filgrastim biosimilars...
Abstract: Biosimilars are hypothesized to contribute to lowering health care costs by entering the market at a discounted price compared with their reference biologics. Until recently, only filgrastim biosimilars...
...
09/13/2018
Journal of Clinical Pathways
Research in Review
Reducing Cancer Drug Waste May Lead to Significant Cost Savings
06/13/2017
JCP Editors
Mitigation strategies may save up to 17% annually in parenteral anticancer drug costs, according to a study published in the Journal of Oncology Practice (published online June 12, 2017;...
Mitigation strategies may save up to 17% annually in parenteral anticancer drug costs, according to a study published in the Journal of Oncology Practice (published online June 12, 2017;...
...
06/13/2017
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

Dermatology Week
November 13 ⁠–⁠ November 16
Psych Congress Primary Care Online Series
November 14 ⁠–⁠ November 15
November 23 ⁠–⁠ November 24
December 4 ⁠–⁠ December 5
Great Debates & Updates in Diabetic Foot
December 6 ⁠–⁠ December 7
AIBD
December 9 ⁠–⁠ December 11
December 9 ⁠–⁠ December 11
Psych Congress Primary Care Online Series
December 12 ⁠–⁠ December 13
December 14 ⁠–⁠ December 15
February 2 ⁠–⁠ February 5
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use